Identification

Name
Indoramin
Accession Number
DB08950
Type
Small Molecule
Groups
Withdrawn
Description

Indoramin is a discontinued piperidine antiadrenergic drug with the trade names Baratol and Doralese. It is a selective alpha-1 adrenergic antagonist with no reflex tachycardia and direct myocardial depression action.

Structure
Thumb
Synonyms
  • Indoramina
  • Indoramine
External IDs
Wy 21901
Product Ingredients
IngredientUNIICASInChI Key
Indoramin HydrochlorideDQ0Z3K8W9238821-52-2AFJSFHAKSSWOKG-UHFFFAOYSA-N
International/Other Brands
Baratol (Amdipharm) / Doralese (GlaxoSmithKline) / Doralese (Chemidex) / Vidora (Leurquin) / Wydora (Riemser)
Categories
UNII
0Z802HMY7H
CAS number
26844-12-2
Weight
Average: 347.4534
Monoisotopic: 347.199762437
Chemical Formula
C22H25N3O
InChI Key
JXZZEXZZKAWDSP-UHFFFAOYSA-N
InChI
InChI=1S/C22H25N3O/c26-22(17-6-2-1-3-7-17)24-19-11-14-25(15-12-19)13-10-18-16-23-21-9-5-4-8-20(18)21/h1-9,16,19,23H,10-15H2,(H,24,26)
IUPAC Name
N-{1-[2-(1H-indol-3-yl)ethyl]piperidin-4-yl}benzenecarboximidic acid
SMILES
OC(=NC1CCN(CCC2=CNC3=CC=CC=C23)CC1)C1=CC=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UAlpha-1A adrenergic receptor
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineIndoramin may decrease the vasoconstricting activities of 4-Methoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Indoramin.Experimental
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Indoramin.Approved, Investigational
AcemetacinThe therapeutic efficacy of Indoramin can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineIndoramin may increase the antihypertensive activities of Acepromazine.Approved, Vet Approved
AdrafinilIndoramin may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AgmatineThe risk or severity of hypotension can be increased when Indoramin is combined with Agmatine.Experimental, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Indoramin is combined with Aldesleukin.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Indoramin.Approved, Investigational
AliskirenIndoramin may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Indoramin.Approved, Withdrawn
AmbrisentanIndoramin may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmibegronIndoramin may decrease the vasoconstricting activities of Amibegron.Investigational
AmifostineIndoramin may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Indoramin is combined with Amiloride.Approved
AmiodaroneAmiodarone may increase the orthostatic hypotensive activities of Indoramin.Approved, Investigational
AmitrazIndoramin may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmitriptylineIndoramin may increase the antihypertensive activities of Amitriptyline.Approved
AmlodipineIndoramin may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Indoramin.Approved, Illicit
AmoxapineIndoramin may increase the antihypertensive activities of Amoxapine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Indoramin.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Indoramin.Approved, Investigational
AmrinoneThe risk or severity of hypotension can be increased when Indoramin is combined with Amrinone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Indoramin is combined with Amyl Nitrite.Approved
AnisodamineIndoramin may decrease the vasoconstricting activities of Anisodamine.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Indoramin.Approved, Investigational
ApraclonidineIndoramin may decrease the vasoconstricting activities of Apraclonidine.Approved
AranidipineThe risk or severity of hypotension can be increased when Indoramin is combined with Aranidipine.Approved, Investigational
ArbutamineIndoramin may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolIndoramin may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Indoramin.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Indoramin.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Indoramin.Approved, Investigational
AsenapineIndoramin may increase the antihypertensive activities of Asenapine.Approved
AtenololAtenolol may increase the orthostatic hypotensive activities of Indoramin.Approved
AvanafilAvanafil may increase the hypotensive activities of Indoramin.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Indoramin is combined with Azelnidipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Indoramin is combined with Azilsartan medoxomil.Approved, Investigational
AzimilideThe risk or severity of hypotension can be increased when Indoramin is combined with Azimilide.Investigational
BambuterolIndoramin may decrease the vasoconstricting activities of Bambuterol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Indoramin.Experimental
BarbitalBarbital may increase the hypotensive activities of Indoramin.Illicit
BarnidipineIndoramin may increase the antihypertensive activities of Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Indoramin.Experimental
BenazeprilIndoramin may increase the hypotensive activities of Benazepril.Approved, Investigational
BencyclaneThe risk or severity of hypotension can be increased when Indoramin is combined with Bencyclane.Experimental
BendroflumethiazideIndoramin may increase the hypotensive activities of Bendroflumethiazide.Approved
BenidipineThe risk or severity of hypotension can be increased when Indoramin is combined with Benidipine.Approved, Investigational
BenmoxinBenmoxin may increase the hypotensive activities of Indoramin.Withdrawn
BenzphetamineIndoramin may decrease the vasoconstricting activities of Benzphetamine.Approved, Illicit
BepridilIndoramin may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Indoramin.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Indoramin.Approved
BevantololIndoramin may increase the antihypertensive activities of Bevantolol.Approved
BietaserpineIndoramin may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostIndoramin may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BioallethrinThe risk or severity of hypotension can be increased when Indoramin is combined with Bioallethrin.Approved, Experimental
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Indoramin.Approved
BitolterolIndoramin may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Indoramin.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Indoramin.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Indoramin.Approved, Investigational
BQ-123Indoramin may increase the hypotensive activities of BQ-123.Investigational
BretyliumIndoramin may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleIndoramin may increase the antihypertensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the antihypertensive activities of Indoramin.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Indoramin.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Indoramin.Approved, Investigational
BucindololIndoramin may increase the antihypertensive activities of Bucindolol.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Indoramin.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Indoramin is combined with Bumetanide.Approved
BunazosinIndoramin may increase the antihypertensive activities of Bunazosin.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Indoramin.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Indoramin.Approved
CadralazineIndoramin may increase the hypotensive activities of Cadralazine.Experimental
CafedrineIndoramin may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Indoramin is combined with Canagliflozin.Approved
CandesartanIndoramin may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilIndoramin may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilIndoramin may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilIndoramin may increase the hypotensive activities of Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Indoramin.Approved, Investigational
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Indoramin is combined with Carboxyamidotriazole.Investigational
CaroverineThe risk or severity of hypotension can be increased when Indoramin is combined with Caroverine.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Indoramin.Withdrawn
CarteololCarteolol may increase the orthostatic hypotensive activities of Indoramin.Approved
CarvedilolCarvedilol may increase the antihypertensive activities of Indoramin.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Indoramin.Approved, Investigational
ChlorothiazideIndoramin may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineIndoramin may increase the antihypertensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorthalidoneIndoramin may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineIndoramin may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilIndoramin may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of hypotension can be increased when Indoramin is combined with Cilnidipine.Approved, Investigational
CinnarizineThe risk or severity of hypotension can be increased when Indoramin is combined with Cinnarizine.Approved, Investigational
CirazolineIndoramin may decrease the vasoconstricting activities of Cirazoline.Experimental
ClenbuterolIndoramin may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of hypotension can be increased when Indoramin is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Indoramin.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Indoramin.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Indoramin.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Indoramin.Experimental
ClozapineIndoramin may increase the antihypertensive activities of Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Indoramin.Approved, Investigational
CryptenamineIndoramin may increase the hypotensive activities of Cryptenamine.Approved
CyclandelateThe risk or severity of hypotension can be increased when Indoramin is combined with Cyclandelate.Approved
CyclopenthiazideIndoramin may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideIndoramin may increase the hypotensive activities of Cyclothiazide.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Indoramin is combined with Dapagliflozin.Approved
DapiprazoleIndoramin may increase the antihypertensive activities of Dapiprazole.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Indoramin.Investigational
DarodipineThe risk or severity of hypotension can be increased when Indoramin is combined with Darodipine.Experimental
DebrisoquinDebrisoquin may increase the hypotensive activities of Indoramin.Approved, Investigational
DelaprilIndoramin may increase the hypotensive activities of Delapril.Investigational
DeserpidineIndoramin may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Indoramin.Approved
DesipramineDesipramine may increase the orthostatic hypotensive activities of Indoramin.Approved, Investigational
DetomidineIndoramin may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexmedetomidineIndoramin may decrease the vasoconstricting activities of Dexmedetomidine.Approved, Vet Approved
DextroamphetamineIndoramin may increase the antihypertensive activities of Dextroamphetamine.Approved, Illicit
DiazoxideDiazoxide may increase the hypotensive activities of Indoramin.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Indoramin is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineIndoramin may increase the hypotensive activities of Diethylnorspermine.Investigational
DihydralazineIndoramin may increase the hypotensive activities of Dihydralazine.Approved, Investigational
DihydroergotamineIndoramin may decrease the vasoconstricting activities of Dihydroergotamine.Approved, Investigational
DiltiazemIndoramin may increase the hypotensive activities of Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Indoramin is combined with Dinutuximab.Approved, Investigational
DipivefrinIndoramin may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleDipyridamole may increase the hypotensive activities of Indoramin.Approved
DL-MethylephedrineIndoramin may decrease the vasoconstricting activities of DL-Methylephedrine.Approved
DobutamineIndoramin may decrease the vasoconstricting activities of Dobutamine.Approved
DopexamineIndoramin may decrease the vasoconstricting activities of Dopexamine.Approved, Investigational
DorzolamideIndoramin may increase the hypotensive activities of Dorzolamide.Approved
DotarizineThe risk or severity of hypotension can be increased when Indoramin is combined with Dotarizine.Investigational
DoxazosinDoxazosin may increase the antihypertensive activities of Indoramin.Approved
DoxepinIndoramin may increase the antihypertensive activities of Doxepin.Approved, Investigational
DoxofyllineIndoramin may decrease the vasoconstricting activities of Doxofylline.Approved, Investigational
DronedaroneIndoramin may increase the antihypertensive activities of Dronedarone.Approved
DroperidolIndoramin may increase the antihypertensive activities of Droperidol.Approved, Vet Approved
DroxidopaIndoramin may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineIndoramin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineIndoramin may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Indoramin is combined with Empagliflozin.Approved
EnalaprilIndoramin may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatIndoramin may increase the hypotensive activities of Enalaprilat.Approved
EndralazineIndoramin may increase the hypotensive activities of Endralazine.Experimental
EpanololEpanolol may increase the orthostatic hypotensive activities of Indoramin.Experimental
EperisoneThe risk or severity of hypotension can be increased when Indoramin is combined with Eperisone.Approved, Investigational
EphedraIndoramin may decrease the vasoconstricting activities of Ephedra.Approved, Nutraceutical, Withdrawn
EphedrineIndoramin may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineIndoramin may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineIndoramin may increase the antihypertensive activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Indoramin is combined with Eplerenone.Approved
EpoprostenolIndoramin may increase the hypotensive activities of Epoprostenol.Approved
EprosartanIndoramin may increase the hypotensive activities of Eprosartan.Approved
ErgonovineIndoramin may decrease the vasoconstricting activities of Ergonovine.Approved
ErgotamineIndoramin may decrease the vasoconstricting activities of Ergotamine.Approved
EsatenololEsatenolol may increase the orthostatic hypotensive activities of Indoramin.Experimental
EscitalopramIndoramin may increase the antihypertensive activities of Escitalopram.Approved, Investigational
EsmololEsmolol may increase the orthostatic hypotensive activities of Indoramin.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Indoramin is combined with Etacrynic acid.Approved, Investigational
EtafedrineIndoramin may decrease the vasoconstricting activities of Etafedrine.Approved
EthosuximideThe risk or severity of hypotension can be increased when Indoramin is combined with Ethosuximide.Approved
EtilefrineIndoramin may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EtomidateIndoramin may decrease the vasoconstricting activities of Etomidate.Approved
FelodipineIndoramin may increase the hypotensive activities of Felodipine.Approved, Investigational
FendilineThe risk or severity of hypotension can be increased when Indoramin is combined with Fendiline.Withdrawn
FenoldopamIndoramin may increase the hypotensive activities of Fenoldopam.Approved
FenoterolIndoramin may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
Ferulic acidIndoramin may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Indoramin.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Indoramin is combined with Fish oil.Approved, Nutraceutical
FlunarizineThe risk or severity of hypotension can be increased when Indoramin is combined with Flunarizine.Approved
FlupentixolIndoramin may increase the antihypertensive activities of Flupentixol.Approved, Investigational, Withdrawn
FluspirileneThe risk or severity of hypotension can be increased when Indoramin is combined with Fluspirilene.Approved, Investigational
FormoterolIndoramin may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosinoprilIndoramin may increase the hypotensive activities of Fosinopril.Approved
FostamatinibFostamatinib may increase the hypotensive activities of Indoramin.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Indoramin.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Indoramin is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of hypotension can be increased when Indoramin is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of hypotension can be increased when Indoramin is combined with Gallopamil.Investigational
GuanabenzIndoramin may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelIndoramin may increase the hypotensive activities of Guanadrel.Approved
GuanazodineIndoramin may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineIndoramin may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Indoramin.Approved, Investigational
GuanoclorIndoramin may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzIndoramin may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanIndoramin may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Indoramin.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Indoramin.Experimental
HexamethoniumIndoramin may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Indoramin.Approved
HexoprenalineIndoramin may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineIndoramin may decrease the vasoconstricting activities of Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Indoramin.Experimental
HydralazineHydralazine may increase the hypotensive activities of Indoramin.Approved
HydrochlorothiazideIndoramin may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideIndoramin may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
IloperidoneIndoramin may increase the antihypertensive activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Indoramin.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Indoramin.Investigational
ImipramineIndoramin may increase the antihypertensive activities of Imipramine.Approved
IndacaterolIndoramin may decrease the vasoconstricting activities of Indacaterol.Approved
IndapamideIndoramin may increase the hypotensive activities of Indapamide.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Indoramin.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Indoramin.Withdrawn
IrbesartanIndoramin may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Indoramin.Approved
IsoetarineIndoramin may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Indoramin is combined with Isoflurane.Approved, Vet Approved
IsomethepteneIndoramin may decrease the vasoconstricting activities of Isometheptene.Approved
IsoprenalineIndoramin may decrease the vasoconstricting activities of Isoprenaline.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Indoramin is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Indoramin is combined with Isosorbide Mononitrate.Approved
IsoxsuprineIndoramin may decrease the vasoconstricting activities of Isoxsuprine.Approved, Withdrawn
IsradipineIndoramin may increase the hypotensive activities of Isradipine.Approved, Investigational
KetanserinIndoramin may increase the hypotensive activities of Ketanserin.Investigational
LabetalolLabetalol may increase the antihypertensive activities of Indoramin.Approved
LacidipineIndoramin may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of hypotension can be increased when Indoramin is combined with Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Indoramin.Investigational
LatanoprostIndoramin may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipineIndoramin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Indoramin is combined with Levetiracetam.Approved, Investigational
LevobetaxololLevobetaxolol may increase the orthostatic hypotensive activities of Indoramin.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Indoramin is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Indoramin is combined with Levobupivacaine.Approved, Investigational
LevodopaIndoramin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosalbutamolIndoramin may decrease the vasoconstricting activities of Levosalbutamol.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Indoramin is combined with Levosimendan.Approved, Investigational
LidoflazineThe risk or severity of hypotension can be increased when Indoramin is combined with Lidoflazine.Experimental
LinsidomineIndoramin may increase the hypotensive activities of Linsidomine.Experimental
LisdexamfetamineIndoramin may increase the antihypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilIndoramin may increase the hypotensive activities of Lisinopril.Approved, Investigational
LofexidineIndoramin may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoperamideThe risk or severity of hypotension can be increased when Indoramin is combined with Loperamide.Approved
LosartanIndoramin may increase the hypotensive activities of Losartan.Approved
MacitentanIndoramin may increase the hypotensive activities of Macitentan.Approved
Magnesium sulfateThe risk or severity of hypotension can be increased when Indoramin is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineIndoramin may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Indoramin is combined with Mannitol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Indoramin.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Indoramin.Approved, Investigational
MedetomidineIndoramin may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MentholThe risk or severity of hypotension can be increased when Indoramin is combined with Menthol.Approved
MephentermineIndoramin may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Indoramin.Experimental
MetaraminolIndoramin may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethamphetamineIndoramin may decrease the vasoconstricting activities of Methamphetamine.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Indoramin is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Indoramin.Approved
MethoserpidineIndoramin may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineIndoramin may increase the antihypertensive activities of Methotrimeprazine.Approved, Investigational
MethoxamineIndoramin may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenamineIndoramin may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of hypotension can be increased when Indoramin is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Indoramin is combined with Methyclothiazide.Approved
MethyldopaIndoramin may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Indoramin.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Indoramin.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Indoramin.Approved
MetipranololIndoramin may increase the hypotensive activities of Metipranolol.Approved
MetolazoneIndoramin may increase the hypotensive activities of Metolazone.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Indoramin.Approved, Investigational
MetyrosineIndoramin may increase the hypotensive activities of Metyrosine.Approved
MibefradilIndoramin may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineIndoramin may decrease the vasoconstricting activities of Midodrine.Approved
MinaprineMinaprine may increase the hypotensive activities of Indoramin.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Indoramin.Approved, Investigational
MirabegronIndoramin may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Indoramin.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Indoramin.Approved, Investigational
MoexiprilIndoramin may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Indoramin.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Indoramin is combined with Morphine.Approved, Investigational
MoxonidineIndoramin may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzolimineIndoramin may increase the hypotensive activities of Muzolimine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Indoramin is combined with Nabilone.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Indoramin.Approved
NaftopidilIndoramin may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineIndoramin may decrease the vasoconstricting activities of Naphazoline.Approved
NebivololNebivolol may increase the orthostatic hypotensive activities of Indoramin.Approved, Investigational
NefazodoneIndoramin may increase the antihypertensive activities of Nefazodone.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Indoramin is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Indoramin.Withdrawn
NicardipineIndoramin may increase the antihypertensive activities of Nicardipine.Approved, Investigational
NicergolineIndoramin may increase the antihypertensive activities of Nicergoline.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Indoramin.Approved, Investigational
NifedipineThe risk or severity of hypotension can be increased when Indoramin is combined with Nifedipine.Approved
NiguldipineIndoramin may increase the antihypertensive activities of Niguldipine.Experimental
NiludipineThe risk or severity of hypotension can be increased when Indoramin is combined with Niludipine.Experimental
NilvadipineIndoramin may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Indoramin is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineIndoramin may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineIndoramin may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineIndoramin may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Indoramin is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Indoramin is combined with Nitroglycerin.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Indoramin.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Indoramin is combined with Nitrous acid.Approved, Investigational
NorepinephrineIndoramin may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineIndoramin may decrease the vasoconstricting activities of Norfenefrine.Experimental
NortriptylineIndoramin may increase the antihypertensive activities of Nortriptyline.Approved
NylidrinIndoramin may decrease the vasoconstricting activities of Nylidrin.Approved
ObinutuzumabIndoramin may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Indoramin.Withdrawn
OctopamineIndoramin may decrease the vasoconstricting activities of Octopamine.Experimental
OlanzapineIndoramin may increase the antihypertensive activities of Olanzapine.Approved, Investigational
OlmesartanIndoramin may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolIndoramin may decrease the vasoconstricting activities of Olodaterol.Approved
OmapatrilatIndoramin may increase the hypotensive activities of Omapatrilat.Investigational
OrciprenalineIndoramin may decrease the vasoconstricting activities of Orciprenaline.Approved
OtiloniumThe risk or severity of hypotension can be increased when Indoramin is combined with Otilonium.Experimental, Investigational
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Indoramin.Approved
OxyfedrineIndoramin may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineIndoramin may decrease the vasoconstricting activities of Oxymetazoline.Approved, Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Indoramin is combined with Paclitaxel.Approved, Vet Approved
PaliperidoneIndoramin may increase the antihypertensive activities of Paliperidone.Approved
PapaverineThe risk or severity of adverse effects can be increased when Indoramin is combined with Papaverine.Approved, Investigational
PargylinePargyline may increase the hypotensive activities of Indoramin.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Indoramin.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Indoramin.Approved, Investigational, Vet Approved
PentoliniumIndoramin may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Indoramin.Approved, Investigational
PergolideIndoramin may decrease the vasoconstricting activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilIndoramin may increase the hypotensive activities of Perindopril.Approved
PhendimetrazineIndoramin may decrease the vasoconstricting activities of Phendimetrazine.Approved, Illicit
PhenelzinePhenelzine may increase the hypotensive activities of Indoramin.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Indoramin.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Indoramin.Approved, Investigational
PhenoxybenzamineIndoramin may increase the antihypertensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Indoramin.Withdrawn
PhentolamineIndoramin may increase the antihypertensive activities of Phentolamine.Approved
PhenylephrineIndoramin may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineIndoramin may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PinacidilPinacidil may increase the hypotensive activities of Indoramin.Approved
PinaveriumThe risk or severity of hypotension can be increased when Indoramin is combined with Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Indoramin.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Indoramin is combined with Pipamperone.Approved, Investigational
PirbuterolIndoramin may decrease the vasoconstricting activities of Pirbuterol.Approved
PirlindolePirlindole may increase the hypotensive activities of Indoramin.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Indoramin.Withdrawn
PizotifenIndoramin may increase the antihypertensive activities of Pizotifen.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Indoramin.Experimental
PolythiazideIndoramin may increase the hypotensive activities of Polythiazide.Approved
PractololPractolol may increase the orthostatic hypotensive activities of Indoramin.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Indoramin is combined with Pramipexole.Approved, Investigational
PrazosinPrazosin may increase the antihypertensive activities of Indoramin.Approved
PrenalterolIndoramin may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineThe risk or severity of hypotension can be increased when Indoramin is combined with Prenylamine.Withdrawn
PrimidonePrimidone may increase the hypotensive activities of Indoramin.Approved, Vet Approved
ProcaineProcaine may increase the hypotensive activities of Indoramin.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Indoramin.Approved, Investigational
ProcaterolIndoramin may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
PromazineIndoramin may increase the antihypertensive activities of Promazine.Approved, Vet Approved
PropafenonePropafenone may increase the orthostatic hypotensive activities of Indoramin.Approved
PropericiazineIndoramin may increase the antihypertensive activities of Propericiazine.Approved, Investigational
PropiomazineIndoramin may increase the antihypertensive activities of Propiomazine.Approved
PropiverineIndoramin may increase the antihypertensive activities of Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Indoramin is combined with Propofol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Indoramin.Approved, Investigational
ProtokylolIndoramin may decrease the vasoconstricting activities of Protokylol.Approved, Vet Approved
PseudoephedrineIndoramin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuetiapineIndoramin may increase the antihypertensive activities of Quetiapine.Approved
QuinaprilIndoramin may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineIndoramin may increase the antihypertensive activities of Quinidine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Indoramin.Approved
RacepinephrineIndoramin may increase the antihypertensive activities of Racepinephrine.Approved
RactopamineIndoramin may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamiprilIndoramin may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Indoramin.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Indoramin is combined with Remifentanil.Approved
RemikirenIndoramin may increase the hypotensive activities of Remikiren.Approved
ReproterolIndoramin may decrease the vasoconstricting activities of Reproterol.Investigational
RescinnamineIndoramin may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Indoramin.Approved, Investigational
RilmenidineIndoramin may increase the hypotensive activities of Rilmenidine.Approved, Investigational
RimiterolIndoramin may decrease the vasoconstricting activities of Rimiterol.Experimental
RiociguatIndoramin may increase the hypotensive activities of Riociguat.Approved
RisperidoneIndoramin may increase the hypotensive activities of Risperidone.Approved, Investigational
RitobegronIndoramin may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineIndoramin may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RituximabIndoramin may increase the hypotensive activities of Rituximab.Approved
RomifidineIndoramin may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleThe risk or severity of adverse effects can be increased when Indoramin is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Indoramin is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Indoramin is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Indoramin is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Indoramin.Withdrawn
SalbutamolIndoramin may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolIndoramin may decrease the vasoconstricting activities of Salmeterol.Approved
SaprisartanIndoramin may increase the hypotensive activities of Saprisartan.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Indoramin.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Indoramin.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Indoramin is combined with Seletracetam.Investigational
SelexipagIndoramin may increase the hypotensive activities of Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Indoramin is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Indoramin.Approved, Investigational
SilodosinSilodosin may increase the antihypertensive activities of Indoramin.Approved
SitaxentanIndoramin may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SolabegronIndoramin may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Indoramin.Approved
SpiraprilIndoramin may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Indoramin is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Indoramin is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Indoramin is combined with Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Indoramin is combined with Sulpiride.Approved, Investigational
SynephrineIndoramin may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Indoramin.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Indoramin.Investigational
TamsulosinTamsulosin may increase the antihypertensive activities of Indoramin.Approved, Investigational
TelmisartanIndoramin may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilIndoramin may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerazosinTerazosin may increase the antihypertensive activities of Indoramin.Approved
TerbutalineTerbutaline may increase the orthostatic hypotensive activities of Indoramin.Approved
TerlipressinIndoramin may increase the hypotensive activities of Terlipressin.Approved, Investigational
TerodilineThe risk or severity of hypotension can be increased when Indoramin is combined with Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Indoramin.Experimental
TetrahydropalmatineIndoramin may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolineIndoramin may decrease the vasoconstricting activities of Tetryzoline.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Indoramin is combined with Thalidomide.Approved, Investigational, Withdrawn
TheodrenalineIndoramin may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineTheophylline may increase the hypotensive activities of Indoramin.Approved
ThiamylalThiamylal may increase the hypotensive activities of Indoramin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Indoramin.Approved, Vet Approved
ThioproperazineIndoramin may increase the antihypertensive activities of Thioproperazine.Approved
ThioridazineIndoramin may increase the antihypertensive activities of Thioridazine.Approved, Withdrawn
TiboloneIndoramin may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenIndoramin may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololTimolol may increase the orthostatic hypotensive activities of Indoramin.Approved
TizanidineIndoramin may decrease the vasoconstricting activities of Tizanidine.Approved, Investigational
TolazolineIndoramin may increase the antihypertensive activities of Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Indoramin is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Indoramin is combined with Tolfenamic Acid.Approved, Investigational
TolonidineIndoramin may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Indoramin.Approved
TorasemideIndoramin may increase the hypotensive activities of Torasemide.Approved
TrandolaprilIndoramin may increase the hypotensive activities of Trandolapril.Approved
TranilastThe risk or severity of hypotension can be increased when Indoramin is combined with Tranilast.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Indoramin.Approved, Investigational
TravoprostIndoramin may increase the hypotensive activities of Travoprost.Approved
TrazodoneIndoramin may increase the antihypertensive activities of Trazodone.Approved, Investigational
TreprostinilIndoramin may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Indoramin is combined with Tretinoin.Approved, Investigational, Nutraceutical
TretoquinolIndoramin may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriamtereneThe risk or severity of adverse effects can be increased when Indoramin is combined with Triamterene.Approved
TrichlormethiazideIndoramin may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineIndoramin may increase the antihypertensive activities of Trifluoperazine.Approved, Investigational
TrimazosinIndoramin may increase the antihypertensive activities of Trimazosin.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Indoramin is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Indoramin is combined with Trimethadione.Approved
TrimethaphanTrimethaphan may increase the hypotensive activities of Indoramin.Approved, Investigational
TrimipramineIndoramin may increase the antihypertensive activities of Trimipramine.Approved
TulobuterolIndoramin may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Indoramin.Approved, Investigational
UnoprostoneIndoramin may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilIndoramin may increase the antihypertensive activities of Urapidil.Investigational
ValsartanIndoramin may increase the hypotensive activities of Valsartan.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Indoramin.Approved
VerapamilIndoramin may increase the antihypertensive activities of Verapamil.Approved
VilanterolIndoramin may decrease the vasoconstricting activities of Vilanterol.Approved
VincamineIndoramin may increase the hypotensive activities of Vincamine.Experimental
VinpocetineIndoramin may increase the hypotensive activities of Vinpocetine.Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Indoramin is combined with WIN 55212-2.Experimental
XamoterolIndoramin may decrease the vasoconstricting activities of Xamoterol.Experimental
XipamideIndoramin may increase the hypotensive activities of Xipamide.Experimental
XylazineIndoramin may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineIndoramin may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Indoramin.Approved, Investigational, Vet Approved
ZiconotideThe risk or severity of hypotension can be increased when Indoramin is combined with Ziconotide.Approved
ZiprasidoneIndoramin may increase the antihypertensive activities of Ziprasidone.Approved
ZofenoprilIndoramin may increase the hypotensive activities of Zofenopril.Experimental
ZonisamideThe risk or severity of hypotension can be increased when Indoramin is combined with Zonisamide.Approved, Investigational
ZuclopenthixolIndoramin may increase the antihypertensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,527,761

General References
Not Available
External Links
KEGG Drug
D04531
PubChem Compound
33625
PubChem Substance
310264915
ChemSpider
31014
BindingDB
50033113
ChEBI
135470
ChEMBL
CHEMBL279516
Drugs.com
Drugs.com Drug Page
Wikipedia
Indoramin
ATC Codes
C02CA02 — Indoramin
MSDS
Download (17.2 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)208-210U.S. Patent 3,527,761
Predicted Properties
PropertyValueSource
Water Solubility0.00498 mg/mLALOGPS
logP4.02ALOGPS
logP3.02ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)8.47ChemAxon
pKa (Strongest Basic)9.59ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area51.62 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity106.46 m3·mol-1ChemAxon
Polarizability40.94 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as tryptamines and derivatives. These are compounds containing the tryptamine backbone, which is structurally characterized by an indole ring substituted at the 3-position by an ethanamine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Tryptamines and derivatives
Direct Parent
Tryptamines and derivatives
Alternative Parents
3-alkylindoles / Benzamides / Benzoyl derivatives / Aralkylamines / Substituted pyrroles / Piperidines / Heteroaromatic compounds / Trialkylamines / Secondary carboxylic acid amides / Amino acids and derivatives
show 5 more
Substituents
Tryptamine / 3-alkylindole / Benzamide / Benzoic acid or derivatives / Indole / Benzoyl / Aralkylamine / Monocyclic benzene moiety / Piperidine / Benzenoid
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G: Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol. 1995 Jan 16;288(2):201-7. [PubMed:7536677]
  2. Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, et al.: The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8. [PubMed:8183249]

Drug created on May 27, 2014 13:11 / Updated on July 02, 2018 20:41